Skip to content

osaühing Pharmal

Registry code (registrikood) 10099034Private limited company (Osaühing)VAT EE100526646Activity (EMTAK 47731): Ravimite jaemüükActive

Harku vald, Harju County · Financial data: annual reports up to 2025; tax data up to 2026 Q3

Revenue (2025)
€1.3M
▲ 7.6% vs 2024
Profit before tax (2025)
-€4.4k
Employees, FTE (2025)
6
State taxes paid, last 4 quarters
€95k

Revenue, profit and employees, 2019–2025

€1.1M2019€1.0M2020€1.0M2021€1.3M2022€1.2M2023€1.2M2024€1.3M2025
YearRevenue (müügitulu)Operating profit (ärikasum)Net profitEquity (omakapital)Employees, FTE
2019€1,082,550-€14,288-€14,305€14,5617
2020€1,004,173-€16,193-€16,193-€1,6327
2021€1,034,294-€12,262-€12,262-€13,8946
2022€1,264,220€133,516€133,516€119,6227
2023€1,240,382-€43,555-€43,544€56,0786
2024€1,247,970-€29,861-€29,851€26,2276
2025€1,342,285-€4,373-€4,370€21,8566

Balance sheet summary

YearCashTotal assetsCurrent liabilitiesNon-current liabilitiesEquity
2019€10,462€193,507€178,946€0€14,561
2020€10,288€173,047€174,679€0-€1,632
2021€8,645€161,373€175,267€0-€13,894
2022€164,659€306,240€186,618€0€119,622
2023€99,989€249,056€192,978€0€56,078
2024€33,295€180,622€154,395€0€26,227
2025€49,788€227,168€205,312€0€21,856

Calculated ratios

Net profit margin = net profit ÷ revenue. Equity ratio = equity ÷ total assets. Seedata sources & methodology for how each figure is derived.

Quarterly tax and turnover data (EMTA)

QuarterState taxes paidWage taxesTurnoverEmployees
2022 Q1€21,311€17,102€292,7229
2022 Q2€22,082€17,455€282,05110
2022 Q3€22,850€20,256€333,38710
2022 Q4€24,180€17,450€338,51610
2023 Q1€23,930€19,582€301,5649
2023 Q2€23,050€18,959€303,2499
2023 Q3€33,354€24,038€311,5928
2023 Q4€22,714€17,986€316,7737
2024 Q1€23,138€19,004€325,0568
2024 Q2€21,492€17,650€297,56510
2024 Q3€22,752€19,418€340,01011
2024 Q4€20,845€16,755€308,84810
2025 Q1€20,421€17,595€305,41610
2025 Q2€23,116€19,711€317,99910
2025 Q3€22,572€18,681€335,28610
2025 Q4€22,499€18,502€345,6139
2026 Q1€24,217€20,802€359,7308
2026 Q2€23,685€17,727€353,3688
2026 Q3€24,985€19,148€388,7648

Source: EMTA quarterly published data, as of 10 October 2026. Covers state taxes and wage taxes actually paid and turnover and employee counts as declared by the company, not the annual report figures above.

About this data

In the 2025 financial year (period 1 January 2025–31 December 2025), osaühing Pharmal reported revenue of €1,342,285.

The company recorded a net loss of €4,370 in the 2025 financial year.

Revenue increased by 7.6% from €1,247,970 in 2024 to €1,342,285 in 2025.

Revenue grew at a compound annual rate of 3.6% between 2019 and 2025.

Equity accounted for 9.6% of total assets of €227,168 at the end of the 2025 reporting period.

With 6 full-time-equivalent employees in 2025, revenue per employee was €223,714.

Across the 4 most recent quarters declared to EMTA, up to Q3 2026, osaühing Pharmal reported €1,447,475 in turnover.

EMTA recorded 8 employees for the quarter ending Q3 2026, compared with 6 full-time-equivalent employees in the 2025 annual report.

Browse

Source

Source: Estonian e-Business Register open data (Centre of Registers and Information Systems, RIK), licence CC BY-SA 4.0, modified; Estonian Tax and Customs Board (EMTA) quarterly data. Downloaded 2026-11-16. This is not an official register extract — see ariregister.rik.ee.

Company data on this site is available under CC BY-SA 4.0.

To request a correction or the removal of this page, use the contact form. Removal requests are handled within 30 days, no justification required.